Connexin connection (IMAGE)
Caption
For the first time, Zhi Sheng and his research team at Virginia Tech identified connexin 43’s role in activating the PI3K/Akt signaling pathway that becomes faulty in aggressive forms of cancer, including glioblastomas. They successfully interrupted this pathway by applying alphaCT11 – a connexin 43 agonist molecule – to selectively bind to P13K, as rendered above.
Credit
(Sheng Lab/Virginia Tech)
Usage Restrictions
None
License
Original content